PubMed:16371368
Annnotations
GlyCosmos6-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 246-254 | Body_part | denotes | juvenile | http://purl.obolibrary.org/obo/UBERON_0007021 |
T2 | 326-350 | Body_part | denotes | myeloid progenitor cells | http://purl.obolibrary.org/obo/CL_0000839 |
T3 | 354-365 | Body_part | denotes | granulocyte | http://purl.obolibrary.org/obo/CL_0000094 |
T4 | 366-376 | Body_part | denotes | macrophage | http://purl.obolibrary.org/obo/CL_0000235 |
T5 | 804-822 | Body_part | denotes | hematopoietic cell | http://purl.obolibrary.org/obo/CL_0000988 |
T6 | 1182-1200 | Body_part | denotes | hematopoietic cell | http://purl.obolibrary.org/obo/CL_0000988 |
sonoma2
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T-0 | 108-117 | VAR | denotes | Mutations |
T-1 | 121-126 | GENE | denotes | SHP-2 |
T-2 | 144-149 | REG | denotes | cause |
T-3 | 150-165 | POSREG | denotes | hyperactivation |
T-4 | 173-191 | MPA | denotes | catalytic activity |
T-5 | 202-212 | REG | denotes | identified |
T-6 | 222-231 | DISEASE | denotes | leukemias |
T-7 | 246-278 | DISEASE | denotes | juvenile myelomonocytic leukemia |
T-8 | 289-302 | REG | denotes | characterized |
T-9 | 306-322 | POSREG | denotes | hypersensitivity |
T-10 | 326-350 | CPA | denotes | myeloid progenitor cells |
T-11 | 354-402 | GENE | denotes | granulocyte macrophage colony-stimulating factor |
T-12 | 407-425 | GENE | denotes | interleukin (IL)-3 |
T-13 | 470-486 | POSREG | denotes | gain-of-function |
T-14 | 488-491 | POSREG | denotes | GOF |
T-15 | 493-502 | VAR | denotes | mutations |
T-16 | 512-518 | REG | denotes | induce |
T-17 | 519-545 | DISEASE | denotes | hematopoietic malignancies |
T-18 | 609-614 | GENE | denotes | SHP-2 |
T-19 | 615-620 | REG | denotes | plays |
T-20 | 642-646 | GENE | denotes | IL-3 |
T-21 | 729-743 | POSREG | denotes | overexpression |
T-22 | 779-789 | NEGREG | denotes | attenuates |
T-23 | 790-803 | GENE | denotes | IL-3-mediated |
T-24 | 804-831 | CPA | denotes | hematopoietic cell function |
T-25 | 840-851 | POSREG | denotes | accelerated |
T-26 | 852-869 | MPA | denotes | dephosphorylation |
T-27 | 873-878 | GENE | denotes | STAT5 |
T-28 | 939-948 | DISEASE | denotes | leukemias |
T-29 | 964-974 | REG | denotes | attributed |
T-30 | 982-991 | POSREG | denotes | increased |
T-31 | 992-1010 | MPA | denotes | catalytic activity |
T-32 | 1014-1017 | POSREG | denotes | GOF |
T-33 | 1018-1024 | VAR | denotes | mutant |
T-34 | 1025-1030 | GENE | denotes | SHP-2 |
T-35 | 1032-1035 | POSREG | denotes | GOF |
T-36 | 1043-1048 | GENE | denotes | SHP-2 |
T-37 | 1059-1065 | POSREG | denotes | gained |
T-38 | 1077-1087 | MPA | denotes | capacities |
T-39 | 1131-1138 | REG | denotes | effects |
T-40 | 1144-1147 | POSREG | denotes | GOF |
T-41 | 1148-1156 | VAR | denotes | mutation |
T-42 | 1167-1172 | GENE | denotes | SHP-2 |
T-43 | 1182-1209 | CPA | denotes | hematopoietic cell function |
T-44 | 1214-1218 | GENE | denotes | IL-3 |
T-45 | 1283-1288 | GENE | denotes | SHP-2 |
T-46 | 1320-1333 | VAR | denotes | E76K mutation |
T-47 | 1334-1340 | REG | denotes | caused |
T-48 | 1341-1367 | DISEASE | denotes | myeloproliferative disease |
T-49 | 1410-1419 | NEGREG | denotes | decreased |
T-50 | 1420-1443 | CPA | denotes | hematopoietic potential |
T-51 | 1494-1507 | VAR | denotes | E76K mutation |
T-52 | 1548-1557 | POSREG | denotes | increased |
T-53 | 1558-1570 | INTERACTION | denotes | interactions |
T-54 | 1574-1580 | VAR | denotes | mutant |
T-55 | 1581-1586 | GENE | denotes | SHP-2 |
T-56 | 1592-1596 | GENE | denotes | Grb2 |
T-57 | 1598-1602 | GENE | denotes | Gab2 |
T-58 | 1608-1611 | GENE | denotes | p85 |
T-59 | 1613-1620 | REG | denotes | leading |
T-60 | 1624-1639 | POSREG | denotes | hyperactivation |
T-61 | 1664-1709 | PATHWAY | denotes | phosphatidylinositol 3-kinase (PI3K) pathways |
T-62 | 1748-1756 | POSREG | denotes | increase |
T-63 | 1764-1782 | MPA | denotes | catalytic activity |
T-64 | 1784-1801 | MPA | denotes | dephosphorylation |
T-65 | 1805-1810 | GENE | denotes | STAT5 |
T-66 | 1814-1819 | GENE | denotes | SHP-2 |
T-67 | 1820-1824 | VAR | denotes | E76K |
T-68 | 1829-1837 | NEGREG | denotes | dampened |
T-69 | 1875-1880 | GENE | denotes | SHP-2 |
T-70 | 1905-1919 | VAR | denotes | C459S mutation |
T-71 | 1947-1955 | POSREG | denotes | increase |
T-72 | 1960-1971 | INTERACTION | denotes | interaction |
T-73 | 1977-1981 | GENE | denotes | Gab2 |
T-74 | 1989-1996 | POSREG | denotes | enhance |
T-75 | 2019-2031 | PATHWAY | denotes | PI3K pathway |
T-76 | 2095-2103 | POSREG | denotes | elevated |
T-77 | 2104-2122 | MPA | denotes | catalytic activity |
T-78 | 2136-2143 | REG | denotes | changes |
T-79 | 2171-2183 | INTERACTION | denotes | interactions |
T-80 | 2192-2195 | POSREG | denotes | GOF |
T-81 | 2203-2208 | GENE | denotes | SHP-2 |
T-82 | 2237-2241 | REG | denotes | play |
T-83 | 2255-2259 | REG | denotes | role |
R-0 | T-0 | T-2 | CauseOf | Mutations,cause |
R-1 | T-0 | T-3 | CauseOf | Mutations,hyperactivation |
R-2 | T-0 | T-9 | CauseOf | Mutations,hypersensitivity |
R-3 | T-1 | T-0 | ThemeOf | SHP-2,Mutations |
R-4 | T-4 | T-3 | ThemeOf | catalytic activity,hyperactivation |
R-5 | T-4 | T-5 | ThemeOf | catalytic activity,identified |
R-6 | T-6 | T-3 | ThemeOf | leukemias,hyperactivation |
R-7 | T-6 | T-5 | ThemeOf | leukemias,identified |
R-8 | T-6 | T-8 | ThemeOf | leukemias,characterized |
R-9 | T-6 | T-9 | ThemeOf | leukemias,hypersensitivity |
R-10 | T-7 | T-2 | ThemeOf | juvenile myelomonocytic leukemia,cause |
R-11 | T-7 | T-3 | ThemeOf | juvenile myelomonocytic leukemia,hyperactivation |
R-12 | T-7 | T-5 | ThemeOf | juvenile myelomonocytic leukemia,identified |
R-13 | T-7 | T-8 | ThemeOf | juvenile myelomonocytic leukemia,characterized |
R-14 | T-7 | T-9 | ThemeOf | juvenile myelomonocytic leukemia,hypersensitivity |
R-15 | T-9 | T-8 | ThemeOf | hypersensitivity,characterized |
R-16 | T-10 | T-9 | ThemeOf | myeloid progenitor cells,hypersensitivity |
R-17 | T-10 | T-8 | ThemeOf | myeloid progenitor cells,characterized |
R-18 | T-11 | T-8 | ThemeOf | granulocyte macrophage colony-stimulating factor,characterized |
R-19 | T-11 | T-9 | ThemeOf | granulocyte macrophage colony-stimulating factor,hypersensitivity |
R-20 | T-11 | T-10 | ThemeOf | granulocyte macrophage colony-stimulating factor,myeloid progenitor cells |
R-21 | T-12 | T-9 | ThemeOf | interleukin (IL)-3,hypersensitivity |
R-22 | T-12 | T-10 | ThemeOf | interleukin (IL)-3,myeloid progenitor cells |
R-47 | T-35 | T-37 | CauseOf | GOF,gained |
R-57 | T-46 | T-49 | CauseOf | E76K mutation,decreased |
R-58 | T-48 | T-47 | ThemeOf | myeloproliferative disease,caused |
R-59 | T-50 | T-49 | ThemeOf | hematopoietic potential,decreased |
R-60 | T-51 | T-52 | CauseOf | E76K mutation,increased |
R-61 | T-51 | T-59 | CauseOf | E76K mutation,leading |
R-62 | T-51 | T-60 | CauseOf | E76K mutation,hyperactivation |
R-63 | T-53 | T-52 | ThemeOf | interactions,increased |
R-64 | T-54 | T-53 | ThemeOf | mutant,interactions |
R-65 | T-54 | T-59 | CauseOf | mutant,leading |
R-66 | T-54 | T-60 | CauseOf | mutant,hyperactivation |
R-67 | T-55 | T-53 | ThemeOf | SHP-2,interactions |
R-68 | T-55 | T-54 | ThemeOf | SHP-2,mutant |
R-69 | T-56 | T-53 | ThemeOf | Grb2,interactions |
R-70 | T-56 | T-54 | ThemeOf | Grb2,mutant |
R-71 | T-57 | T-53 | ThemeOf | Gab2,interactions |
R-72 | T-57 | T-54 | ThemeOf | Gab2,mutant |
R-73 | T-58 | T-53 | ThemeOf | p85,interactions |
R-94 | T-81 | T-79 | ThemeOf | SHP-2,interactions |
R-95 | T-83 | T-82 | ThemeOf | role,play |
R-23 | T-14 | T-16 | CauseOf | GOF,induce |
R-24 | T-15 | T-13 | CauseOf | mutations,gain-of-function |
R-25 | T-15 | T-16 | CauseOf | mutations,induce |
R-26 | T-17 | T-16 | ThemeOf | hematopoietic malignancies,induce |
R-27 | T-18 | T-19 | ThemeOf | SHP-2,plays |
R-28 | T-20 | T-19 | ThemeOf | IL-3,plays |
R-29 | T-21 | T-22 | CauseOf | overexpression,attenuates |
R-30 | T-21 | T-25 | CauseOf | overexpression,accelerated |
R-31 | T-23 | T-22 | ThemeOf | IL-3-mediated,attenuates |
R-32 | T-24 | T-23 | ThemeOf | hematopoietic cell function,IL-3-mediated |
R-33 | T-24 | T-22 | ThemeOf | hematopoietic cell function,attenuates |
R-34 | T-26 | T-25 | ThemeOf | dephosphorylation,accelerated |
R-35 | T-27 | T-26 | ThemeOf | STAT5,dephosphorylation |
R-36 | T-27 | T-25 | ThemeOf | STAT5,accelerated |
R-37 | T-28 | T-29 | ThemeOf | leukemias,attributed |
R-38 | T-28 | T-30 | ThemeOf | leukemias,increased |
R-39 | T-31 | T-30 | ThemeOf | catalytic activity,increased |
R-40 | T-31 | T-32 | ThemeOf | catalytic activity,GOF |
R-41 | T-33 | T-30 | CauseOf | mutant,increased |
R-42 | T-33 | T-32 | CauseOf | mutant,GOF |
R-43 | T-33 | T-35 | CauseOf | mutant,GOF |
R-44 | T-33 | T-37 | CauseOf | mutant,gained |
R-45 | T-34 | T-31 | ThemeOf | SHP-2,catalytic activity |
R-46 | T-34 | T-33 | ThemeOf | SHP-2,mutant |
R-48 | T-36 | T-38 | ThemeOf | SHP-2,capacities |
R-49 | T-38 | T-37 | ThemeOf | capacities,gained |
R-50 | T-39 | T-40 | ThemeOf | effects,GOF |
R-51 | T-41 | T-40 | CauseOf | mutation,GOF |
R-52 | T-42 | T-39 | ThemeOf | SHP-2,effects |
R-53 | T-42 | T-41 | ThemeOf | SHP-2,mutation |
R-54 | T-43 | T-39 | ThemeOf | hematopoietic cell function,effects |
R-55 | T-43 | T-40 | ThemeOf | hematopoietic cell function,GOF |
R-56 | T-46 | T-47 | CauseOf | E76K mutation,caused |
R-74 | T-58 | T-54 | ThemeOf | p85,mutant |
R-75 | T-61 | T-60 | ThemeOf | phosphatidylinositol 3-kinase (PI3K) pathways,hyperactivation |
R-76 | T-63 | T-62 | ThemeOf | catalytic activity,increase |
R-77 | T-64 | T-62 | ThemeOf | dephosphorylation,increase |
R-78 | T-65 | T-64 | ThemeOf | STAT5,dephosphorylation |
R-79 | T-64 | T-68 | ThemeOf | dephosphorylation,dampened |
R-80 | T-65 | T-67 | ThemeOf | STAT5,E76K |
R-81 | T-66 | T-64 | ThemeOf | SHP-2,dephosphorylation |
R-82 | T-66 | T-67 | ThemeOf | SHP-2,E76K |
R-83 | T-67 | T-62 | CauseOf | E76K,increase |
R-84 | T-67 | T-68 | CauseOf | E76K,dampened |
R-85 | T-69 | T-70 | ThemeOf | SHP-2,C459S mutation |
R-86 | T-70 | T-71 | CauseOf | C459S mutation,increase |
R-87 | T-70 | T-74 | CauseOf | C459S mutation,enhance |
R-88 | T-72 | T-71 | ThemeOf | interaction,increase |
R-89 | T-73 | T-72 | ThemeOf | Gab2,interaction |
R-90 | T-75 | T-74 | ThemeOf | PI3K pathway,enhance |
R-91 | T-77 | T-76 | ThemeOf | catalytic activity,elevated |
R-92 | T-79 | T-78 | ThemeOf | interactions,changes |
R-93 | T-79 | T-80 | ThemeOf | interactions,GOF |
sonoma
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T-0 | 0-7 | REG | denotes | Effects |
T-1 | 33-49 | POSREG | denotes | gain-of-function |
T-2 | 50-58 | VAR | denotes | mutation |
T-3 | 62-79 | GENE | denotes | SHP-2 phosphatase |
T-4 | 108-117 | VAR | denotes | Mutations |
T-5 | 121-138 | GENE | denotes | SHP-2 phosphatase |
T-6 | 144-149 | REG | denotes | cause |
T-7 | 150-165 | POSREG | denotes | hyperactivation |
T-8 | 173-191 | MPA | denotes | catalytic activity |
T-9 | 202-212 | REG | denotes | identified |
T-10 | 222-231 | DISEASE | denotes | leukemias |
T-11 | 246-278 | DISEASE | denotes | juvenile myelomonocytic leukemia |
T-12 | 289-302 | REG | denotes | characterized |
T-13 | 306-322 | POSREG | denotes | hypersensitivity |
T-14 | 470-486 | POSREG | denotes | gain-of-function |
T-15 | 488-491 | POSREG | denotes | GOF |
T-16 | 493-502 | VAR | denotes | mutations |
T-17 | 506-511 | GENE | denotes | SHP-2 |
T-18 | 512-518 | REG | denotes | induce |
T-19 | 519-545 | DISEASE | denotes | hematopoietic malignancies |
T-20 | 609-614 | GENE | denotes | SHP-2 |
T-21 | 729-743 | POSREG | denotes | overexpression |
T-22 | 773-778 | GENE | denotes | SHP-2 |
T-23 | 779-789 | NEGREG | denotes | attenuates |
T-24 | 804-831 | CPA | denotes | hematopoietic cell function |
T-25 | 840-851 | POSREG | denotes | accelerated |
T-26 | 852-869 | MPA | denotes | dephosphorylation |
T-27 | 873-878 | GENE | denotes | STAT5 |
T-28 | 922-938 | GENE | denotes | SHP-2-associated |
T-29 | 939-948 | DISEASE | denotes | leukemias |
T-30 | 964-974 | REG | denotes | attributed |
T-31 | 982-991 | POSREG | denotes | increased |
T-32 | 992-1010 | MPA | denotes | catalytic activity |
T-33 | 1014-1017 | POSREG | denotes | GOF |
T-34 | 1018-1024 | VAR | denotes | mutant |
T-35 | 1025-1030 | GENE | denotes | SHP-2 |
T-36 | 1032-1035 | POSREG | denotes | GOF |
T-37 | 1036-1042 | VAR | denotes | mutant |
T-38 | 1043-1048 | GENE | denotes | SHP-2 |
T-39 | 1059-1065 | POSREG | denotes | gained |
T-40 | 1131-1138 | REG | denotes | effects |
T-41 | 1144-1147 | POSREG | denotes | GOF |
T-42 | 1148-1156 | VAR | denotes | mutation |
T-43 | 1160-1165 | GENE | denotes | SHP-2 |
T-44 | 1167-1172 | GENE | denotes | SHP-2 |
T-45 | 1173-1177 | VAR | denotes | E76K |
T-46 | 1182-1209 | CPA | denotes | hematopoietic cell function |
T-47 | 1283-1288 | GENE | denotes | SHP-2 |
T-48 | 1314-1319 | GENE | denotes | SHP-2 |
T-49 | 1320-1333 | VAR | denotes | E76K mutation |
T-50 | 1334-1340 | REG | denotes | caused |
T-51 | 1341-1367 | DISEASE | denotes | myeloproliferative disease |
T-52 | 1404-1409 | GENE | denotes | SHP-2 |
T-53 | 1410-1419 | NEGREG | denotes | decreased |
T-54 | 1420-1443 | CPA | denotes | hematopoietic potential |
T-55 | 1494-1507 | VAR | denotes | E76K mutation |
T-56 | 1548-1557 | POSREG | denotes | increased |
T-57 | 1558-1570 | INTERACTION | denotes | interactions |
T-58 | 1574-1580 | VAR | denotes | mutant |
T-59 | 1581-1586 | GENE | denotes | SHP-2 |
T-60 | 1592-1596 | GENE | denotes | Grb2 |
T-61 | 1598-1602 | GENE | denotes | Gab2 |
T-62 | 1608-1611 | GENE | denotes | p85 |
T-63 | 1613-1620 | REG | denotes | leading |
T-64 | 1624-1639 | POSREG | denotes | hyperactivation |
T-65 | 1748-1756 | POSREG | denotes | increase |
T-66 | 1764-1782 | MPA | denotes | catalytic activity |
T-67 | 1784-1801 | MPA | denotes | dephosphorylation |
T-68 | 1805-1810 | GENE | denotes | STAT5 |
T-69 | 1814-1819 | GENE | denotes | SHP-2 |
T-70 | 1820-1824 | VAR | denotes | E76K |
T-71 | 1829-1837 | NEGREG | denotes | dampened |
T-72 | 1866-1874 | NEGREG | denotes | inactive |
T-73 | 1875-1880 | GENE | denotes | SHP-2 |
T-74 | 1881-1885 | VAR | denotes | E76K |
T-75 | 1905-1919 | VAR | denotes | C459S mutation |
T-76 | 1947-1955 | POSREG | denotes | increase |
T-77 | 1960-1971 | INTERACTION | denotes | interaction |
T-78 | 1977-1981 | GENE | denotes | Gab2 |
T-79 | 1989-1996 | POSREG | denotes | enhance |
T-80 | 2019-2031 | PATHWAY | denotes | PI3K pathway |
T-81 | 2095-2103 | POSREG | denotes | elevated |
T-82 | 2104-2122 | MPA | denotes | catalytic activity |
T-83 | 2136-2143 | REG | denotes | changes |
T-84 | 2196-2202 | VAR | denotes | mutant |
T-85 | 2203-2208 | GENE | denotes | SHP-2 |
T-86 | 2237-2241 | REG | denotes | play |
T-87 | 2255-2259 | REG | denotes | role |
T-88 | 2263-2276 | GENE | denotes | SHP-2-related |
T-89 | 2277-2291 | DISEASE | denotes | leukemigenesis |
R-0 | T-0 | T-2 | CauseOf | Effects,mutation |
R-1 | T-0 | T-3 | ThemeOf | Effects,SHP-2 phosphatase |
R-2 | T-1 | T-2 | CauseOf | gain-of-function,mutation |
R-3 | T-1 | T-3 | ThemeOf | gain-of-function,SHP-2 phosphatase |
R-4 | T-2 | T-3 | ThemeOf | mutation,SHP-2 phosphatase |
R-5 | T-4 | T-5 | ThemeOf | Mutations,SHP-2 phosphatase |
R-6 | T-4 | T-6 | CauseOf | Mutations,cause |
R-7 | T-4 | T-7 | CauseOf | Mutations,hyperactivation |
R-8 | T-4 | T-9 | CauseOf | Mutations,identified |
R-9 | T-4 | T-12 | CauseOf | Mutations,characterized |
R-10 | T-4 | T-13 | CauseOf | Mutations,hypersensitivity |
R-11 | T-5 | T-10 | A | SHP-2 phosphatase,leukemias |
R-12 | T-5 | T-11 | A | SHP-2 phosphatase,juvenile myelomonocytic leukemia |
R-13 | T-6 | T-8 | ThemeOf | cause,catalytic activity |
R-14 | T-6 | T-10 | ThemeOf | cause,leukemias |
R-15 | T-6 | T-11 | ThemeOf | cause,juvenile myelomonocytic leukemia |
R-16 | T-7 | T-8 | ThemeOf | hyperactivation,catalytic activity |
R-17 | T-7 | T-9 | ThemeOf | hyperactivation,identified |
R-18 | T-7 | T-10 | ThemeOf | hyperactivation,leukemias |
R-19 | T-7 | T-11 | ThemeOf | hyperactivation,juvenile myelomonocytic leukemia |
R-20 | T-8 | T-9 | ThemeOf | catalytic activity,identified |
R-21 | T-8 | T-12 | ThemeOf | catalytic activity,characterized |
R-22 | T-8 | T-13 | ThemeOf | catalytic activity,hypersensitivity |
R-23 | T-9 | T-10 | ThemeOf | identified,leukemias |
R-24 | T-9 | T-11 | ThemeOf | identified,juvenile myelomonocytic leukemia |
R-25 | T-9 | T-12 | ThemeOf | identified,characterized |
R-26 | T-10 | T-12 | ThemeOf | leukemias,characterized |
R-27 | T-10 | T-13 | ThemeOf | leukemias,hypersensitivity |
R-28 | T-11 | T-12 | ThemeOf | juvenile myelomonocytic leukemia,characterized |
R-29 | T-11 | T-13 | ThemeOf | juvenile myelomonocytic leukemia,hypersensitivity |
R-30 | T-12 | T-13 | ThemeOf | characterized,hypersensitivity |
R-31 | T-14 | T-16 | CauseOf | gain-of-function,mutations |
R-32 | T-14 | T-18 | CauseOf | gain-of-function,induce |
R-33 | T-15 | T-16 | CauseOf | GOF,mutations |
R-34 | T-15 | T-17 | ThemeOf | GOF,SHP-2 |
R-35 | T-15 | T-18 | CauseOf | GOF,induce |
R-36 | T-16 | T-17 | ThemeOf | mutations,SHP-2 |
R-37 | T-16 | T-18 | CauseOf | mutations,induce |
R-38 | T-17 | T-18 | ThemeOf | SHP-2,induce |
R-39 | T-17 | T-19 | A | SHP-2,hematopoietic malignancies |
R-40 | T-18 | T-19 | ThemeOf | induce,hematopoietic malignancies |
R-106 | T-57 | T-61 | ThemeOf | interactions,Gab2 |
R-41 | T-21 | T-22 | ThemeOf | overexpression,SHP-2 |
R-42 | T-21 | T-23 | CauseOf | overexpression,attenuates |
R-43 | T-21 | T-25 | CauseOf | overexpression,accelerated |
R-44 | T-22 | T-23 | ThemeOf | SHP-2,attenuates |
R-45 | T-23 | T-24 | ThemeOf | attenuates,hematopoietic cell function |
R-46 | T-23 | T-25 | CauseOf | attenuates,accelerated |
R-47 | T-25 | T-26 | ThemeOf | accelerated,dephosphorylation |
R-48 | T-25 | T-27 | ThemeOf | accelerated,STAT5 |
R-49 | T-26 | T-27 | ThemeOf | dephosphorylation,STAT5 |
R-50 | T-28 | T-31 | CauseOf | SHP-2-associated,increased |
R-51 | T-29 | T-30 | ThemeOf | leukemias,attributed |
R-52 | T-29 | T-35 | A | leukemias,SHP-2 |
R-53 | T-30 | T-32 | ThemeOf | attributed,catalytic activity |
R-54 | T-30 | T-33 | CauseOf | attributed,GOF |
R-55 | T-30 | T-34 | CauseOf | attributed,mutant |
R-56 | T-31 | T-32 | ThemeOf | increased,catalytic activity |
R-57 | T-31 | T-33 | CauseOf | increased,GOF |
R-58 | T-31 | T-34 | CauseOf | increased,mutant |
R-59 | T-31 | T-35 | ThemeOf | increased,SHP-2 |
R-60 | T-32 | T-33 | ThemeOf | catalytic activity,GOF |
R-61 | T-32 | T-34 | ThemeOf | catalytic activity,mutant |
R-62 | T-32 | T-35 | ThemeOf | catalytic activity,SHP-2 |
R-63 | T-33 | T-34 | CauseOf | GOF,mutant |
R-64 | T-33 | T-35 | ThemeOf | GOF,SHP-2 |
R-65 | T-34 | T-35 | ThemeOf | mutant,SHP-2 |
R-66 | T-36 | T-37 | CauseOf | GOF,mutant |
R-67 | T-36 | T-38 | ThemeOf | GOF,SHP-2 |
R-68 | T-36 | T-39 | CauseOf | GOF,gained |
R-69 | T-37 | T-38 | ThemeOf | mutant,SHP-2 |
R-70 | T-37 | T-39 | CauseOf | mutant,gained |
R-71 | T-38 | T-39 | ThemeOf | SHP-2,gained |
R-72 | T-40 | T-41 | ThemeOf | effects,GOF |
R-73 | T-40 | T-42 | CauseOf | effects,mutation |
R-74 | T-40 | T-43 | ThemeOf | effects,SHP-2 |
R-75 | T-40 | T-44 | ThemeOf | effects,SHP-2 |
R-76 | T-40 | T-46 | ThemeOf | effects,hematopoietic cell function |
R-77 | T-41 | T-42 | CauseOf | GOF,mutation |
R-78 | T-41 | T-43 | ThemeOf | GOF,SHP-2 |
R-79 | T-41 | T-44 | ThemeOf | GOF,SHP-2 |
R-80 | T-41 | T-45 | CauseOf | GOF,E76K |
R-81 | T-41 | T-46 | ThemeOf | GOF,hematopoietic cell function |
R-82 | T-42 | T-43 | ThemeOf | mutation,SHP-2 |
R-83 | T-42 | T-44 | ThemeOf | mutation,SHP-2 |
R-84 | T-42 | T-47 | ThemeOf | mutation,SHP-2 |
R-85 | T-43 | T-45 | ThemeOf | SHP-2,E76K |
R-86 | T-44 | T-45 | ThemeOf | SHP-2,E76K |
R-87 | T-45 | T-47 | ThemeOf | E76K,SHP-2 |
R-88 | T-48 | T-49 | ThemeOf | SHP-2,E76K mutation |
R-89 | T-48 | T-51 | A | SHP-2,myeloproliferative disease |
R-90 | T-49 | T-50 | CauseOf | E76K mutation,caused |
R-91 | T-49 | T-53 | CauseOf | E76K mutation,decreased |
R-92 | T-50 | T-51 | ThemeOf | caused,myeloproliferative disease |
R-93 | T-52 | T-53 | ThemeOf | SHP-2,decreased |
R-94 | T-53 | T-54 | ThemeOf | decreased,hematopoietic potential |
R-95 | T-55 | T-56 | CauseOf | E76K mutation,increased |
R-96 | T-55 | T-59 | ThemeOf | E76K mutation,SHP-2 |
R-97 | T-55 | T-63 | CauseOf | E76K mutation,leading |
R-98 | T-55 | T-64 | CauseOf | E76K mutation,hyperactivation |
R-99 | T-56 | T-57 | ThemeOf | increased,interactions |
R-100 | T-56 | T-58 | CauseOf | increased,mutant |
R-101 | T-56 | T-63 | CauseOf | increased,leading |
R-102 | T-56 | T-64 | CauseOf | increased,hyperactivation |
R-103 | T-57 | T-58 | ThemeOf | interactions,mutant |
R-104 | T-57 | T-59 | ThemeOf | interactions,SHP-2 |
R-105 | T-57 | T-60 | ThemeOf | interactions,Grb2 |
R-107 | T-57 | T-62 | ThemeOf | interactions,p85 |
R-108 | T-58 | T-59 | ThemeOf | mutant,SHP-2 |
R-109 | T-58 | T-60 | ThemeOf | mutant,Grb2 |
R-110 | T-58 | T-61 | ThemeOf | mutant,Gab2 |
R-111 | T-58 | T-62 | ThemeOf | mutant,p85 |
R-112 | T-58 | T-63 | CauseOf | mutant,leading |
R-113 | T-58 | T-64 | CauseOf | mutant,hyperactivation |
R-114 | T-63 | T-64 | CauseOf | leading,hyperactivation |
R-115 | T-65 | T-66 | ThemeOf | increase,catalytic activity |
R-116 | T-65 | T-67 | ThemeOf | increase,dephosphorylation |
R-117 | T-65 | T-68 | ThemeOf | increase,STAT5 |
R-118 | T-65 | T-69 | ThemeOf | increase,SHP-2 |
R-119 | T-65 | T-70 | CauseOf | increase,E76K |
R-120 | T-65 | T-71 | CauseOf | increase,dampened |
R-121 | T-66 | T-67 | ThemeOf | catalytic activity,dephosphorylation |
R-122 | T-66 | T-69 | ThemeOf | catalytic activity,SHP-2 |
R-123 | T-66 | T-71 | ThemeOf | catalytic activity,dampened |
R-124 | T-67 | T-68 | ThemeOf | dephosphorylation,STAT5 |
R-125 | T-67 | T-69 | ThemeOf | dephosphorylation,SHP-2 |
R-126 | T-67 | T-70 | ThemeOf | dephosphorylation,E76K |
R-127 | T-67 | T-71 | ThemeOf | dephosphorylation,dampened |
R-128 | T-68 | T-70 | ThemeOf | STAT5,E76K |
R-129 | T-68 | T-71 | ThemeOf | STAT5,dampened |
R-130 | T-69 | T-70 | ThemeOf | SHP-2,E76K |
R-131 | T-69 | T-71 | ThemeOf | SHP-2,dampened |
R-132 | T-72 | T-73 | ThemeOf | inactive,SHP-2 |
R-133 | T-72 | T-74 | CauseOf | inactive,E76K |
R-134 | T-72 | T-75 | CauseOf | inactive,C459S mutation |
R-135 | T-72 | T-76 | CauseOf | inactive,increase |
R-136 | T-72 | T-79 | CauseOf | inactive,enhance |
R-137 | T-73 | T-74 | ThemeOf | SHP-2,E76K |
R-138 | T-73 | T-75 | ThemeOf | SHP-2,C459S mutation |
R-139 | T-73 | T-77 | ThemeOf | SHP-2,interaction |
R-140 | T-74 | T-76 | CauseOf | E76K,increase |
R-141 | T-74 | T-79 | CauseOf | E76K,enhance |
R-142 | T-75 | T-76 | CauseOf | C459S mutation,increase |
R-143 | T-75 | T-79 | CauseOf | C459S mutation,enhance |
R-144 | T-76 | T-77 | ThemeOf | increase,interaction |
R-145 | T-76 | T-78 | ThemeOf | increase,Gab2 |
R-146 | T-76 | T-79 | CauseOf | increase,enhance |
R-147 | T-77 | T-78 | ThemeOf | interaction,Gab2 |
R-148 | T-77 | T-79 | ThemeOf | interaction,enhance |
R-149 | T-77 | T-80 | ThemeOf | interaction,PI3K pathway |
R-150 | T-79 | T-80 | ThemeOf | enhance,PI3K pathway |
R-151 | T-81 | T-82 | ThemeOf | elevated,catalytic activity |
R-152 | T-81 | T-83 | CauseOf | elevated,changes |
R-153 | T-81 | T-84 | CauseOf | elevated,mutant |
R-154 | T-81 | T-86 | CauseOf | elevated,play |
R-155 | T-82 | T-83 | ThemeOf | catalytic activity,changes |
R-156 | T-83 | T-84 | CauseOf | changes,mutant |
R-157 | T-83 | T-85 | ThemeOf | changes,SHP-2 |
R-158 | T-83 | T-86 | CauseOf | changes,play |
R-159 | T-83 | T-87 | CauseOf | changes,role |
R-160 | T-83 | T-88 | CauseOf | changes,SHP-2-related |
R-161 | T-83 | T-89 | ThemeOf | changes,leukemigenesis |
R-162 | T-84 | T-85 | ThemeOf | mutant,SHP-2 |
R-163 | T-84 | T-86 | CauseOf | mutant,play |
R-164 | T-84 | T-87 | CauseOf | mutant,role |
R-165 | T-85 | T-86 | ThemeOf | SHP-2,play |
R-166 | T-85 | T-87 | ThemeOf | SHP-2,role |
R-167 | T-86 | T-87 | ThemeOf | play,role |
R-168 | T-86 | T-88 | CauseOf | play,SHP-2-related |
R-169 | T-86 | T-89 | ThemeOf | play,leukemigenesis |
R-170 | T-87 | T-88 | ThemeOf | role,SHP-2-related |
R-171 | T-87 | T-89 | ThemeOf | role,leukemigenesis |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-107 | Sentence | denotes | Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. |
T2 | 108-426 | Sentence | denotes | Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3. |
T3 | 427-571 | Sentence | denotes | However, the molecular mechanisms by which gain-of-function (GOF) mutations of SHP-2 induce hematopoietic malignancies are not fully understood. |
T4 | 572-879 | Sentence | denotes | Our previous studies have shown that SHP-2 plays an essential role in IL-3 signal transduction in both catalytic-dependent and -independent manners and that overexpression (5-6-fold) of wild type (WT) SHP-2 attenuates IL-3-mediated hematopoietic cell function through accelerated dephosphorylation of STAT5. |
T5 | 880-1031 | Sentence | denotes | These results raised the possibility that SHP-2-associated leukemias are not solely attributed to the increased catalytic activity of GOF mutant SHP-2. |
T6 | 1032-1088 | Sentence | denotes | GOF mutant SHP-2 must have gained additional capacities. |
T7 | 1089-1289 | Sentence | denotes | To test this possibility, we investigated effects of a GOF mutation of SHP-2 (SHP-2 E76K) on hematopoietic cell function and IL-3 signal transduction by comparing with those of overexpressed WT SHP-2. |
T8 | 1290-1489 | Sentence | denotes | Our results showed that SHP-2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP-2 decreased hematopoietic potential of the transduced cells in recipient animals. |
T9 | 1490-1710 | Sentence | denotes | The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways. |
T10 | 1711-1838 | Sentence | denotes | In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened. |
T11 | 1839-2032 | Sentence | denotes | Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway. |
T12 | 2033-2292 | Sentence | denotes | Taken together, these studies suggest that in addition to the elevated catalytic activity, fundamental changes in physical and functional interactions between GOF mutant SHP-2 and signaling partners also play an important role in SHP-2-related leukemigenesis. |
GlyCosmos6-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 183-191 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T2 | 326-350 | http://purl.obolibrary.org/obo/CL_0000839 | denotes | myeloid progenitor cells |
T3 | 345-350 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T4 | 804-822 | http://purl.obolibrary.org/obo/CL_0000988 | denotes | hematopoietic cell |
T5 | 818-822 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T6 | 1002-1010 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T7 | 1182-1200 | http://purl.obolibrary.org/obo/CL_0000988 | denotes | hematopoietic cell |
T8 | 1196-1200 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T9 | 1462-1467 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T10 | 1526-1529 | http://purl.obolibrary.org/obo/CLO_0009132 | denotes | Src |
T11 | 1774-1782 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T12 | 2001-2011 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T13 | 2114-2122 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 13-21 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
T2 | 222-231 | Disease | denotes | leukemias | http://purl.obolibrary.org/obo/MONDO_0005059 |
T3 | 246-278 | Disease | denotes | juvenile myelomonocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0011908 |
T4 | 306-322 | Disease | denotes | hypersensitivity | http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271 |
T6 | 939-948 | Disease | denotes | leukemias | http://purl.obolibrary.org/obo/MONDO_0005059 |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 216-221 | OrganismTaxon | denotes | human | NCBItxid:9606 |
T2 | 1371-1375 | OrganismTaxon | denotes | mice | NCBItxid:10088|NCBItxid:10095 |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 150-165 | HP_0000752 | denotes | hyperactivation |
T2 | 222-231 | HP_0001909 | denotes | leukemias |
T3 | 246-278 | HP_0012209 | denotes | juvenile myelomonocytic leukemia |
T4 | 270-278 | HP_0001909 | denotes | leukemia |
T5 | 939-948 | HP_0001909 | denotes | leukemias |
T6 | 1624-1639 | HP_0000752 | denotes | hyperactivation |
DisGeNET5_variant_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
16371368-7#30#34#geners121918464 | 1320-1324 | geners121918464 | denotes | E76K |
16371368-7#51#77#diseaseC0027022 | 1341-1367 | diseaseC0027022 | denotes | myeloproliferative disease |
30#34#geners12191846451#77#diseaseC0027022 | 16371368-7#30#34#geners121918464 | 16371368-7#51#77#diseaseC0027022 | associated_with | E76K,myeloproliferative disease |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
16371368-0#62#67#gene5781 | 62-67 | gene5781 | denotes | SHP-2 |
16371368-0#13#21#diseaseC0023418 | 13-21 | diseaseC0023418 | denotes | leukemia |
16371368-1#246#294#gene1437 | 354-402 | gene1437 | denotes | granulocyte macrophage colony-stimulating factor |
16371368-1#138#170#diseaseC0349639 | 246-278 | diseaseC0349639 | denotes | juvenile myelomonocytic leukemia |
16371368-2#79#84#gene5781 | 506-511 | gene5781 | denotes | SHP-2 |
16371368-2#92#118#diseaseC0376544 | 519-545 | diseaseC0376544 | denotes | hematopoietic malignancies |
16371368-7#24#29#gene5781 | 1314-1319 | gene5781 | denotes | SHP-2 |
16371368-7#114#119#gene5781 | 1404-1409 | gene5781 | denotes | SHP-2 |
16371368-7#51#77#diseaseC0027022 | 1341-1367 | diseaseC0027022 | denotes | myeloproliferative disease |
62#67#gene578113#21#diseaseC0023418 | 16371368-0#62#67#gene5781 | 16371368-0#13#21#diseaseC0023418 | associated_with | SHP-2,leukemia |
246#294#gene1437138#170#diseaseC0349639 | 16371368-1#246#294#gene1437 | 16371368-1#138#170#diseaseC0349639 | associated_with | granulocyte macrophage colony-stimulating factor,juvenile myelomonocytic leukemia |
79#84#gene578192#118#diseaseC0376544 | 16371368-2#79#84#gene5781 | 16371368-2#92#118#diseaseC0376544 | associated_with | SHP-2,hematopoietic malignancies |
24#29#gene578151#77#diseaseC0027022 | 16371368-7#24#29#gene5781 | 16371368-7#51#77#diseaseC0027022 | associated_with | SHP-2,myeloproliferative disease |
114#119#gene578151#77#diseaseC0027022 | 16371368-7#114#119#gene5781 | 16371368-7#51#77#diseaseC0027022 | associated_with | SHP-2,myeloproliferative disease |
kaiyin_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 108-117 | Var | denotes | Mutations |
T2 | 121-126 | Gene | denotes | SHP-2 |
T3 | 127-138 | Enzyme | denotes | phosphatase |
T4 | 150-165 | PosReg | denotes | hyperactivation |
T5 | 173-191 | MPA | denotes | catalytic activity |
T33 | 216-231 | Disease | denotes | human leukemias |
T34 | 246-278 | Disease | denotes | juvenile myelomonocytic leukemia |
T10 | 1314-1319 | Gene | denotes | SHP-2 |
T11 | 1320-1333 | Var | denotes | E76K mutation |
T12 | 1341-1375 | Disease | denotes | myeloproliferative disease in mice |
T13 | 1494-1547 | Var | denotes | E76K mutation in the N-terminal Src homology 2 domain |
T14 | 1548-1557 | PosReg | denotes | increased |
T15 | 1558-1570 | Interaction | denotes | interactions |
T18 | 1574-1580 | Var | denotes | mutant |
T17 | 1581-1586 | Gene | denotes | SHP-2 |
T16 | 1592-1596 | Protein | denotes | Grb2 |
T19 | 1624-1639 | PosReg | denotes | hyperactivation |
T20 | 1643-1709 | Pathway | denotes | IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways |
T25 | 1748-1756 | PosReg | denotes | increase |
T26 | 1764-1782 | MPA | denotes | catalytic activity |
T24 | 1784-1810 | MPA | denotes | dephosphorylation of STAT5 |
T22 | 1814-1819 | Gene | denotes | SHP-2 |
T23 | 1820-1824 | Var | denotes | E76K |
T21 | 1829-1837 | NegReg | denotes | dampened |
T27 | 1852-1919 | Var | denotes | catalytically inactive SHP-2 E76K with an additional C459S mutation |
T28 | 1947-1955 | PosReg | denotes | increase |
T29 | 1960-1971 | Interaction | denotes | interaction |
T30 | 1977-1981 | Protein | denotes | Gab2 |
T31 | 1989-1996 | PosReg | denotes | enhance |
T32 | 2001-2031 | Pathway | denotes | activation of the PI3K pathway |
R1 | T3 | T2 | ThemeOf | phosphatase,SHP-2 |
R10 | T17 | T15 | ThemeOf | SHP-2,interactions |
R11 | T18 | T17 | ThemeOf | mutant,SHP-2 |
R12 | T14 | T19 | CauseOf | increased,hyperactivation |
R13 | T20 | T19 | ThemeOf | IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways,hyperactivation |
R14 | T26 | T25 | ThemeOf | catalytic activity,increase |
R15 | T24 | T21 | ThemeOf | dephosphorylation of STAT5,dampened |
R16 | T23 | T22 | ThemeOf | E76K,SHP-2 |
R17 | T22 | T24 | ThemeOf | SHP-2,dephosphorylation of STAT5 |
R18 | T27 | T28 | CauseOf | catalytically inactive SHP-2 E76K with an additional C459S mutation,increase |
R19 | T29 | T28 | ThemeOf | interaction,increase |
R2 | T2 | T1 | ThemeOf | SHP-2,Mutations |
R20 | T30 | T29 | ThemeOf | Gab2,interaction |
R21 | T27 | T31 | CauseOf | catalytically inactive SHP-2 E76K with an additional C459S mutation,enhance |
R22 | T32 | T31 | ThemeOf | activation of the PI3K pathway,enhance |
R3 | T1 | T4 | CauseOf | Mutations,hyperactivation |
R4 | T5 | T4 | ThemeOf | catalytic activity,hyperactivation |
R5 | T10 | T11 | ThemeOf | SHP-2,E76K mutation |
R6 | T11 | T12 | CauseOf | E76K mutation,myeloproliferative disease in mice |
R7 | T13 | T14 | CauseOf | E76K mutation in the N-terminal Src homology 2 domain,increased |
R8 | T15 | T14 | ThemeOf | interactions,increased |
R9 | T16 | T15 | ThemeOf | Grb2,interactions |
name_no
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 108-117 | Var | denotes | Mutations |
T2 | 121-126 | Gene | denotes | SHP-2 |
T3 | 127-138 | Enzyme | denotes | phosphatase |
T4 | 150-165 | PosReg | denotes | hyperactivation |
T5 | 173-191 | MPA | denotes | catalytic activity |
T33 | 216-231 | Disease | denotes | human leukemias |
T34 | 246-278 | Disease | denotes | juvenile myelomonocytic leukemia |
T10 | 1314-1319 | Gene | denotes | SHP-2 |
T11 | 1320-1333 | Var | denotes | E76K mutation |
T12 | 1341-1375 | Disease | denotes | myeloproliferative disease in mice |
T13 | 1494-1547 | Var | denotes | E76K mutation in the N-terminal Src homology 2 domain |
T14 | 1548-1557 | PosReg | denotes | increased |
T15 | 1558-1570 | Interaction | denotes | interactions |
T18 | 1574-1580 | Var | denotes | mutant |
T17 | 1581-1586 | Gene | denotes | SHP-2 |
T16 | 1592-1596 | Protein | denotes | Grb2 |
T19 | 1624-1639 | PosReg | denotes | hyperactivation |
T20 | 1643-1709 | Pathway | denotes | IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways |
T25 | 1748-1756 | PosReg | denotes | increase |
T26 | 1764-1782 | MPA | denotes | catalytic activity |
T24 | 1784-1810 | MPA | denotes | dephosphorylation of STAT5 |
T22 | 1814-1819 | Gene | denotes | SHP-2 |
T23 | 1820-1824 | Var | denotes | E76K |
T21 | 1829-1837 | NegReg | denotes | dampened |
T27 | 1852-1919 | Var | denotes | catalytically inactive SHP-2 E76K with an additional C459S mutation |
T28 | 1947-1955 | PosReg | denotes | increase |
T29 | 1960-1971 | Interaction | denotes | interaction |
T30 | 1977-1981 | Protein | denotes | Gab2 |
T31 | 1989-1996 | PosReg | denotes | enhance |
T32 | 2001-2031 | Pathway | denotes | activation of the PI3K pathway |
R1 | T3 | T2 | ThemeOf | phosphatase,SHP-2 |
R10 | T17 | T15 | ThemeOf | SHP-2,interactions |
R11 | T18 | T17 | ThemeOf | mutant,SHP-2 |
R12 | T14 | T19 | CauseOf | increased,hyperactivation |
R13 | T20 | T19 | ThemeOf | IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways,hyperactivation |
R14 | T26 | T25 | ThemeOf | catalytic activity,increase |
R15 | T24 | T21 | ThemeOf | dephosphorylation of STAT5,dampened |
R16 | T23 | T22 | ThemeOf | E76K,SHP-2 |
R17 | T22 | T24 | ThemeOf | SHP-2,dephosphorylation of STAT5 |
R18 | T27 | T28 | CauseOf | catalytically inactive SHP-2 E76K with an additional C459S mutation,increase |
R19 | T29 | T28 | ThemeOf | interaction,increase |
R2 | T2 | T1 | ThemeOf | SHP-2,Mutations |
R20 | T30 | T29 | ThemeOf | Gab2,interaction |
R21 | T27 | T31 | CauseOf | catalytically inactive SHP-2 E76K with an additional C459S mutation,enhance |
R22 | T32 | T31 | ThemeOf | activation of the PI3K pathway,enhance |
R3 | T1 | T4 | CauseOf | Mutations,hyperactivation |
R4 | T5 | T4 | ThemeOf | catalytic activity,hyperactivation |
R5 | T10 | T11 | ThemeOf | SHP-2,E76K mutation |
R6 | T11 | T12 | CauseOf | E76K mutation,myeloproliferative disease in mice |
R7 | T13 | T14 | CauseOf | E76K mutation in the N-terminal Src homology 2 domain,increased |
R8 | T15 | T14 | ThemeOf | interactions,increased |
R9 | T16 | T15 | ThemeOf | Grb2,interactions |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 62-67 | gene:5781 | denotes | SHP-2 |
T1 | 13-21 | disease:C0023418 | denotes | leukemia |
R1 | T0 | T1 | associated_with | SHP-2,leukemia |